Symposium Speakers – IoT Application / Personalized Services

IoT is empowering the Utility of The Future

Michael Van Boven

Director Technology

Deloitte Consulting

Michael Van Boven is a Director with Deloitte Consulting who has over 14 years of consulting experience in advising and leading large scale and complex business enablement transformations across a variety of industries. Mr. Van Boven is a leading practitioner and recognized thought leader in Deloitte's emerging IoT technology solutions practice with focus on advising leading electric power and utilities companies with transformation and convergence of their operations and underlying IoT technologies to achieve future vision. Mr. Van Boven is active in industry standards groups and has published whitepapers and presented at leading industry conferences with regards to best practice electric power and utility IoT sensor technology integration approaches and considerations.

Abstract: The Power and Utilities (P&U) industry has been flagged as one of leading sectors in the adoption and deployment of IoT in the marketplace. Although IoT (Smart Sensor technology) is not new to the P&U industry, P&U companies have taken their investment and deployment of IoT and Smart Sensor technology to a new level over the past 5-10 years. Using IoT as central vehicle in helping P&U companies to break out of nearly 100 years of operational stagnation and drive them towards more efficient and effective operations ultimately unlocking new value streams for end customers. Michael will share how recent and future IoT investments by the P&U industry will enable the movement towards the Utility of the Future vision including the next generation set of operational capabilities (e.g. distributed generation, analytics) that could directly impact end consumers' live.

How personalized solutions and IoT can revolutionize the Oil & Gas industry

Elaine Petty

Team Leader Technical Software

Halliburton

Elaine Petty is the Team Lead for the product owners and user experience groups in the Technical Software department for Halliburton Completion Tools. Elaine has past experience leading products and projects in Marketing Technology for industries such as finance, pharmaceutical sales, and hospitality. Elaine earned a Bachelor of Business Administration in Marketing and a Bachelor of Arts in Psychology from Southern Methodist University. She was a Cox BBA Scholar, SMU Scholar, in the SMU University Honors Program and a Scrum Certified Product Owner.

Abstract:
Creating an enterprise solution aimed at enabling everyone within the organization to get the right information at the right time which enable right decision making throughout the life cycle of a job: 1) Tie together all aspects of work life - from customer relations to running a job; 2) Reduce duplicate of effort; 3) Enhance collaboration; 4) Empower decision making. Game changing that makes stronger organization and happier customers. Always connected!

Symposium Speakers –
IoT Application / Personalized Services

Dr. Yang Xie, M.D.

Associate Professor and Director

Quantitative Biomedical Research Center, UT Southwestern Medical Center

Bioinformatics and Personalized Medicine

Dr. Yang Xie, M.D., is the founding Director of both the Quantitative Biomedical Research Center and the Simmons Comprehensive Cancer Center Bioinformatics Core at UT Southwestern Medical Center. Dr. Xie's primary expertise is in integrative analysis of big medical data, developing predictive signatures and personalized medicine. She is currently the principal investigator on an NCI RO1 grant (CA152301) for developing comprehensive statistical models to predict adjuvant chemotherapy response. She leads the Biostatistics, Bioinformatics and Data Integration Cores for three large multi-project center grants.

Abstract:
Randomized clinical trials have demonstrated the survival benefit of adjuvant chemotherapy (ACT) in resected non-small-cell lung cancer (NSCLC). Because the response to standard chemotherapy in lung cancer varies, it would be helpful to prospectively identify patients who will benefit from ACT to guide the treatment plan. In this talk, I will present several studies aiming to identify clinically useful gene expression markers for prognosis and response to adjuvant chemotherapy in lung cancer patients.